Graves' disease Medical Services in China

Graves’ disease is an autoimmune disorder of the endocrine system characterized by overactivity of the thyroid gland (hyperthyroidism), resulting from autoantibodies—primarily thyroid-stimulating immunoglobulins (TSI)—that bind to and chronically activate the thyroid-stimulating hormone (TSH) receptor. This leads to unregulated synthesis and secretion of thyroid hormones (T3 and T4), disrupting metabolic homeostasis. Unlike other forms of hyperthyroidism, Graves’ disease is systemic: it frequently involves extrathyroidal manifestations, most notably Graves’ ophthalmopathy (inflammatory orbital disease causing proptosis, diplopia, and periorbital edema) and, less commonly, pretibial myxedema or acropachy. The pathogenesis centers on loss of immune tolerance to thyroid antigens, with genetic susceptibility (e.g., HLA-DR3, CTLA-4, PTPN22 polymorphisms), environmental triggers—including stress, smoking, iodine excess, and viral infections—and dysregulated T-cell and B-cell responses all contributing to autoantibody production. Epidemiologically, Graves’ disease is the most common cause of hyperthyroidism worldwide, affecting approximately 0.5% of the general population. It exhibits a strong female predominance (female-to-male ratio ~7:1), with peak incidence between ages 30 and 50. Annual incidence ranges from 20 to 50 cases per 100,000 persons in Western populations; data from China suggest comparable rates, though underdiagnosis may occur in rural settings. Key risk factors include personal or family history of autoimmune diseases (e.g., type 1 diabetes, rheumatoid arthritis, vitiligo), cigarette smoking (which markedly increases risk and severity of ophthalmopathy), postpartum status, high dietary iodine intake, and certain medications (e.g., interferon-alpha, alemtuzumab). Untreated or poorly controlled Graves’ disease significantly impairs quality of life: patients commonly report debilitating fatigue, anxiety, insomnia, palpitations, weight loss despite increased appetite, heat intolerance, tremor, and menstrual disturbances. Ocular involvement can cause pain, photophobia, blurred vision, and psychosocial distress due to facial disfigurement. Long-term complications include atrial fibrillation, heart failure, osteoporosis, and thyroid storm—a rare but life-threatening acute exacerbation. Even with treatment, many patients experience persistent symptoms, emotional burden, and functional limitations—particularly those with moderate-to-severe orbitopathy—underscoring the need for multidisciplinary care integrating endocrinology, ophthalmology, and nuclear medicine.

Graves’ disease is an autoimmune disorder characterized by hyperthyroidism due to autoantibodies—primarily thyroid-stimulating immunoglobulins (TSI)—that bind to and chronically activate the TSH receptor on thyroid follicular cells. This results in unregulated synthesis and secretion of thyroid hormones (T3 and T4), leading to systemic manifestations including tachycardia, weight loss, heat intolerance, tremor, anxiety, goiter, and, in up to 30–50% of cases, Graves’ ophthalmopathy (GO). Management requires a multidisciplinary approach coordinated by endocrinologists, with treatment goals centered on restoring euthyroidism, alleviating symptoms, preventing complications (e.g., atrial fibrillation, heart failure, thyroid storm), and addressing extrathyroidal manifestations.

Conservative management forms the cornerstone of initial therapy and includes supportive measures alongside definitive interventions. Patients are advised to avoid iodine-rich foods (e.g., kelp, iodized salt in excess), discontinue stimulants (caffeine, sympathomimetics), and implement stress-reduction strategies, given the potential modulatory role of psychological stress on immune dysregulation. Beta-adrenergic blockade—typically with propranolol (20–80 mg/day) or atenolol (25–100 mg/day)—is initiated early to control adrenergic symptoms (palpitations, tremor, anxiety) while awaiting definitive antithyroid effects. Propranolol also inhibits peripheral conversion of T4 to T3 and may modestly reduce TSI production; it is contraindicated in decompensated heart failure, bronchospastic disease, or severe bradycardia. Nutritional support—including adequate calcium, vitamin D, and caloric intake—is essential, particularly in patients with significant weight loss or osteopenia. Regular monitoring of bone mineral density is recommended in postmenopausal women and long-standing untreated cases.

Pharmacotherapy remains the first-line definitive treatment for most newly diagnosed patients, especially those under age 40, with small-to-moderate goiters, mild disease activity, or contraindications to radioiodine. Antithyroid drugs (ATDs) include methimazole (MMI) and propylthiouracil (PTU). MMI is preferred due to its once-daily dosing, superior efficacy, lower relapse rate, and reduced hepatotoxicity risk. Initial dosing ranges from 10–40 mg/day, titrated downward as thyroid function normalizes (typically over 4–8 weeks). PTU (50–200 mg/day) is reserved for pregnancy (first trimester), lactation (with caution), or thyroid storm due to its additional inhibition of peripheral T4-to-T3 conversion and shorter half-life. Treatment duration is typically 12–18 months, followed by gradual tapering and discontinuation if TSH, free T4, and T3 are normalized and TSI levels decline. Remission rates after ATD withdrawal range from 40–60%, with predictors of sustained remission including female sex, small goiter size, low baseline TSI titers, and absence of smoking or GO. Adverse effects require vigilant monitoring: agranulocytosis (0.2–0.5%), hepatitis (especially with PTU), vasculitis (ANCA-positive), and skin rashes. Complete blood count and liver enzymes should be checked at baseline and repeated if symptoms such as sore throat, fever, jaundice, or arthralgia arise.

Radioactive iodine (RAI, I-131) ablation is the most common definitive therapy in adults in many countries, including China, particularly for patients over age 40, those with large goiters, recurrent hyperthyroidism after ATDs, or contraindications to surgery. A calculated dose (typically 8–15 mCi) is administered orally, resulting in selective destruction of hyperfunctioning thyroid tissue over 3–6 months. Hypothyroidism develops in >80% of patients within one year and necessitates lifelong levothyroxine replacement. RAI is contraindicated in pregnancy, breastfeeding, and active moderate-to-severe GO—where it may exacerbate orbitopathy unless concurrent glucocorticoid prophylaxis (e.g., prednisone 0.4–0.5 mg/kg/day for 1–3 months) is administered. Pre-treatment thyroid ultrasound and radioactive iodine uptake (RAIU) testing are mandatory to confirm diagnosis and exclude autonomous nodules.

Thyroidectomy—total or near-total—is indicated for patients with compressive symptoms (dysphagia, stridor), suspicious thyroid nodules, severe GO unresponsive to immunosuppression, or patient preference. It offers rapid, predictable resolution of hyperthyroidism and eliminates future risk of recurrence or malignancy in the gland. In experienced high-volume centers, complication rates are low: permanent hypoparathyroidism (<2%) and recurrent laryngeal nerve injury (<1%). Preoperative preparation is critical: patients must achieve euthyroidism using ATDs (usually MMI), supplemented with beta-blockade and, in some cases, potassium iodide (Lugol’s solution) for 7–10 days preoperatively to reduce vascularity and intraoperative bleeding. Postoperative care includes calcium and calcitriol supplementation until parathyroid function stabilizes and lifelong levothyroxine replacement.

Treatment advantages in China include widespread access to high-quality, domestically manufactured ATDs and levothyroxine with stringent regulatory oversight by the National Medical Products Administration (NMPA). Advanced imaging (high-resolution thyroid ultrasound with elastography, SPECT/CT for RAIU) and functional assays (third-generation TSH, sensitive free T4/T3, TSI chemiluminescence assays) are routinely available in tertiary hospitals. Multidisciplinary GO management—integrating endocrinology, ophthalmology, and radiation oncology—is increasingly standardized, with intravenous glucocorticoids and teprotumumab now accessible in major academic centers. Moreover, China’s national health insurance system covers ATDs, RAI, and thyroidectomy for Graves’ disease, significantly reducing out-of-pocket burden. Telemedicine platforms facilitate longitudinal follow-up, especially for rural patients, improving adherence and early detection of relapse or complications.

Recovery advice emphasizes strict adherence to prescribed regimens and scheduled monitoring. Patients should attend follow-up visits every 4–6 weeks during ATD therapy, then every 3 months after remission or RAI, and annually thereafter if stable on levothyroxine. Thyroid function tests (TSH, free T4) must be drawn before morning levothyroxine doses. Smoking cessation is non-negotiable: tobacco use doubles the risk of GO progression and reduces response to all therapies. Patients with GO should wear UV-protective sunglasses, use lubricating eye drops, elevate the head during sleep, and seek prompt ophthalmologic evaluation for diplopia or vision changes. Women of childbearing age require preconception counseling: MMI should be switched to PTU before conception, and thyroid function must be optimized prior to pregnancy. Finally, psychosocial support—including cognitive behavioral therapy or peer-led support groups—is encouraged, as anxiety and fatigue often persist despite biochemical euthyroidism. With timely, individualized, and sustained care, the vast majority of patients with Graves’ disease achieve excellent long-term outcomes, preserving quality of life and minimizing morbidity.